**Supplementary Table 1. Survey Responses**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ***Which Components of CER/RE are relevant in your decision making?*** | | | | | | | | | |
|  | **U.S. Respondents, count (n=8)** | | | | | **European Respondents, count (n=6)** | | | |
| Not at all / Slightly relevant | | Moderately / Very / Extremely relevant | | | Not at all / Slightly relevant | Moderately / Very / Extremely relevant | | |
| Direct head to head comparisons of effective interventions |  | | 6 | | | 1 | 5 | | |
| Patient population enrolled in study is representative of real world patients |  | | 5 | | |  | 6 | | |
| Inclusion of hard endpoints such as mortality or hospitalizations that are most meaningful to end-users |  | | 5 | | |  | 6 | | |
| Patient reported outcomes |  | | 6 | | |  | 6 | | |
| Conducted in settings of care where patients are likely to get the treatment | 1 | | 5 | | | 1 | 6 | | |
| Providers of enrolled patients represent  those I am most likely to pay to use the  drug | 4 | | 2 | | |  |  | | |
| Patients are followed less closely so that  their compliance with their medication  more closely resembles that seen in  actual clinical practice | 4 | | 2 | | |  |  | | |
| Budgetary Impact |  | |  | | | 4 | 2 | | |
| Health Resource Utilization |  |  |  | | |  | 6 | | |
| ***Of the evidence you consider or have considered in the past, how frequently did you use each type of evidence (in isolation or in combination with other evidence) in making your coverage or reimbursement decisions?*** | | | | | | | | | |
|  | **U.S. Respondents, count (n=8)** | | | | **European Respondents, count (n=6)** | | | | |
|  | Never or Almost Never | | Occasionally/Sometimes, Almost every time or Every time | | Never or Almost Never | | | Occasionally/Sometimes, Almost every time or Every time | |
| Randomized trial |  | | 6 | |  | | | 6 | |
| Randomized trial in "real-world" settings |  | | 6 | | 2 | | | 4 | |
| A controlled, but not randomized study |  | | 6 | | 2 | | | 3 | |
| Observational data that are prospectively collected at multiple instances over time before and after an intervention occurs |  | | 6 | | 0 | | | 6 | |
| Observational data that are collected over time from patients in a registry |  |  | 6 | | 2 | | | 4 | |
| Study for which electronic health record is used to assess the primary outcome | 2 | | 4 | | 3 | | | 3 | |
| Observational data pulled from administrative claims database1 | 1 | | 5 | | 2 | | | 4 | |
| Systematic reviews of existing RCTs and a statistical summary of the combined findings |  | | 6 | |  | | | 6 | |
| Cluster RCT |  | | 6 | | 2 | | | 4 | |
| Delayed Design trial | 1 | | 4 | | 4 | | | 1 | |
| ***How often do you use prospective observational evidence that incorporates the following analytic techniques?*** | | | | | | | | | |
|  | **U.S. Respondents, count (n=8)** | | | **European Respondents, count (n=6)** | | | | | |
|  | Never or Almost Never | Occasionally/ Sometimes, Almost every time or Every time | | Never or Almost Never | | | | | Occasionally/Sometimes, Almost every time or Every time |
| Propensity Scoring | 2 | 4 | | 3 | | | | | 2 |
| Instrumental Variable Analysis | 4 | 2 | | 4 | | | | | 1 |
| Multivariate Logistic Regression | 1 | 5 | | 1 | | | | | 5 |
| Interrupted Time Series Analysis | 4 | 2 | | 3 | | | | | 2 |
| Decision modeling or simulations that predict long term trial results before long term data have accumulated | 4 | 2 | | 2 | | | | | 4 |
| Indirect comparisons (for example, combining results of an A vs. B trial with a B vs. C trial to estimate A vs. C) | 4 | 2 | | 1 | | | | | 5 |
| Bayesian statistics | 3 | 3 | | 2 | | | | | 4 |
| Cost utility analysis | 3 | 3 | | 1 | | | | | 5 |
| ***How often do you utilize information from the following sources when making coverage or reimbursement decisions for new drugs?*** | | | | | | | | | |
|  | **U.S. Respondents, count (n=8)** | | | **European Respondents, count (n=6)** | | | | | |
|  | Never or Almost never | Occasionally/Sometimes, Almost every time or Every time | | Never or Almost Never | | | | | Occasionally/Sometimes, Almost every time or Every time |
| My health system's own data collection and research efforts\* | 2 | 4 | |  | | | | |  |
| The alliance or trade association to which my health system belongs (e.g., Premier or BC/BS TEC)\* | 3 | 2 | |  | | | | |  |
| The federal government (e.g., NIH, AHRQ)1 |  | 6 | | 1 | | | | | 5 |
| Academic research organizations |  | 6 | | 2 | | | | | 4 |
| Pharmaceutical company research | 1 | 5 | |  | | | | | 6 |

The wording above represents that used in the U.S., the EU wording was identical unless indicated in the following points. 1. The national health system or government funded initiatives